Yale School of Medicine and NYU Grossman School of Medicine demonstrated the validity of 2 new diagnostic tools – the Rapid Opioid Use Disorder Assessment and the Rapid Stimulant Use Disorder Assessment – to be easily administered by non-clinical personnel, to increase treatment access.


